<DOC>
	<DOCNO>NCT00411996</DOCNO>
	<brief_summary>We believe strong rationale study IDV/r 600/100 bid boosted-PI combination , presence RMP , able produce satisfactory PK profile associate adequate antiretroviral potency , tolerability efficacy .</brief_summary>
	<brief_title>The Pharmacokinetics Safety IDV/r With NRTIs HIV/TB Co-infected Patients Receiving Rifampicin</brief_title>
	<detailed_description>The fixed-dose combination d4T+3TC+NVP ( GPOvir ) widely use Thailand since June 2002 . The prevalence NNRTI resistance increase since 2005 . Efavirenz-based antiretroviral therapy ( ART ) prefer patient TB/HIV receive rifampin-containing TB regimen . However , efavirenz use context NNRTI failure , intolerance toxicity . The optimal ART population receive rifampicin remain unknown . Rifabutin , recommend combination boost protease inhibitor ( PI/r ) expensive available Thailand develop country . Ritonavir-boosted indinavir ( IDV/r ) potent cheap boost PI available Thailand . If IDV/r combination rifampin demonstrate suitable pharmacokinetics well tolerate , regimen might prove useful could widely implement . However , high rate gastrointestinal renal toxicity demonstrate Thai patient receive standard dos IDV/r 800/100 BID . We believe strong rationale study IDV/r 600/100 BID combination rifampin able produce satisfactory pharmacokinetic profile , antiretroviral potency , tolerability efficacy .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Confirmed HIV positive voluntary counsel test Aged 18 60 year age Antiretroviral treatment naive CD4+ cell count &lt; 200 cells/mm3 time TB diagnosis ALT &lt; 5 time ULN Serum creatinine &lt; 1.4 mg/dl Haemoglobin &gt; 8 mg/L TB diagnosis ; either probable ( clinical symptom plus chest xray response antiTB medication ) definitive ( sputum AFB culture confirm ) receive plan receive rifampicincontaining antiTB therapy least 2 week period initiation ART No active OI ( CDC class C event ) Able provide write informed consent Current use steroid immunosuppressive agent Current use prohibit medication related compliance drug pharmacokinetics Patients current alcohol illicit substance use opinion site Principal Investigator would conflict aspect conduct trial . Previous exposure nevirapine monotherapy Unlikely able remain followup protocol define period Patients proven suspect acute hepatitis . Patients chronic viral hepatitis eligible provide ALT , AST &lt; 5 x ULN . Karnofsky performance score &lt; 30 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>indinavir/ritonavir</keyword>
	<keyword>HIV/TB</keyword>
	<keyword>rifampicin</keyword>
	<keyword>PK efficacy IDV/RTV 600/100 mg BID rifampicin</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>